Novo Nordisk To Slash Prices On Buzzy Drugs Ozempic and Wegovy

Novo Nordisk, a Danish pharmaceutical company, plans to reduce prices for its popular diabetes and weight-loss drugs, Ozempic and Wegovy, due to increasing competition and ongoing shortages. Despite their high demand and significant contribution to the company’s sales, many patients struggle with the high cost, as insurers often do not cover the medications. This price reduction aligns with challenges from the FTC on Novo's patents and fluctuating financial performance, including a recent dip in stock value despite rising sales.